Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00339638 · ClinicalTrials.gov registry record

Study of Adult T-Cell Leukemia/Lymphoma Among Carriers of HTLV-1

A clinical trial, sponsored by National Cancer Institute (NCI).

Completed
Registry status
228
Enrollment target

NCT00339638: Completed study, sponsored by National Cancer Institute (NCI).

NCT00339638 is a clinical trial that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 228 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00339638 has completed, sponsored by National Cancer Institute (NCI).

COMPLETED
Registry status
228 participants
Enrollment target

Study Summary

This study will identify chemical and protein markers in the blood of people who carry the human T-lymphotropic virus type I (HTLV-I), a virus associated with various pathologies, including an increased risk in adults of a rare and aggressive cancer called adult T cell leukemia/lymphoma (ATL). The study will also examine differences in these markers before and after the onset of ATL. ATL has been reported in every area where HTLV-1 is common, including the Caribbean and parts of Japan, West Africa, the Middle East, South America, and Pacific Melanesia. Risk factors for the disease are largely unknown and seem to vary among those affected in different endemic regions. People who acquire the infection early in life are thought to be at higher risk than those who are infected later. In Japan, men seem to be at greater risk than women, but the same is not evident among the black population in the Caribbean and Brazil. Findings from this study will increase understanding of the cause of ATL and identify differences in tumor characteristics and the course of disease across geographical areas. Study subjects are drawn from among participants in eight studies of HTLV-1 carriers, including the 1) Jamaica Mother-Infant Cohort Study, 2) Jamaica Family Study, 3) Jamaica Food Handlers Study, 4) Miyazaki Cohort Study in Japan, 5) Nagasaki Cohort Study in Japan, 6) Japan Public Health Center-based Prospective Study on Cancer and Cardiovascular Disease, 7) HTLV Outcome Studies in the United States, and 8) GIPH Cohort Study in Brazil. Stored blood samples previously collected from patients in the above studies who did and did not develop ATL will be analyzed for immunologic and genetic factors.

Trial Details

FieldValue
Enrollment Target 228 participants
Start Date 2004-12-21
Est. Completion 2011-05-26

Sponsor

National Cancer Institute (NCI)

3,257 total trials

What the Registry Record Tells You About NCT00339638

The ClinicalTrials.gov registry entry for NCT00339638 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 228 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 0 interventions.

NCT00339638 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00339638 about?

NCT00339638 is a clinical study titled "Study of Adult T-Cell Leukemia/Lymphoma Among Carriers of HTLV-1". This study will identify chemical and protein markers in the blood of people who carry the human T-lymphotropic virus type I (HTLV-I), a virus associated with various pathologies, including an increased risk in adults of a rare and aggressive cancer called adult T cell leukemia/lymphoma (ATL). The s...

What is the current status of trial NCT00339638?

This trial is currently completed. The enrollment target is 228 participants. The study started on 2004-12-21. Estimated completion is 2011-05-26.

Who is sponsoring clinical trial NCT00339638?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.